IDMet (RaDiCo Cohort) (RaDiCo-IDMet)
IDMet
National Cohort on Imprinting Disorders and Their Metabolic Consequences
1 other identifier
observational
2,000
1 country
20
Brief Summary
The goal of this observational study is to describe the natural history of imprinting disorders (IDs) according to their metabolic profile in all patients (adults and children) affected with an ID regardless of the severity of the disease, with a molecular characterization, with a signed informed consent for all subjects, followed in one partner's center. The main questions it aims to answer are:
- Can we identify common metabolic profiles for all imprinted diseases?
- Which imprinting disorders have an impact on the metabolic profiles of IDs?
- Which are the metabolic risks associated to IDs?
- Can we use the metabolic profiles for the clinical classification and prognosis of IDs?
- Are there common therapeutic approaches for all IDs?
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2017
Longer than P75 for all trials
20 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 10, 2017
CompletedFirst Submitted
Initial submission to the registry
June 26, 2023
CompletedFirst Posted
Study publicly available on registry
July 14, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 1, 2028
February 12, 2026
February 1, 2026
11 years
June 26, 2023
February 10, 2026
Conditions
Outcome Measures
Primary Outcomes (4)
The clinical characteristics of IDs in pediatric and adult's patients.
Through study completion, an average of 10 years
The genetic characteristics of IDs in pediatric and adult's patients.
Through study completion, an average of 10 years
The biological characteristics of IDs in pediatric and adult's patients.
Through study completion, an average of 10 years
The morphometric characteristics of IDs in pediatric and adult's patients.
Through study completion, an average of 10 years
Secondary Outcomes (6)
Search for an association between the metabolic phenotype of IDs patients' and their biological profil.
At the time of diagnosis (or at first measurement)
Determination of the prevalence of metabolic abnormalities (MA).
At inclusion
Estimation of the risk for metabolic complications such as obesity, diabetes, cardiovascular disease (CVD), metabolic syndrome.
10 years after
Description of different therapeutic approaches and identification of a common base for all IDs.
Through study completion, an average of 10 years
Variations of quality-of-life scores.
Through study completion, an average of 10 years
- +1 more secondary outcomes
Other Outcomes (5)
Identification of different metabolic profile which allow a clinical classification of IDs.
Through study completion, an average of 10 years
Description and identification of the most relevant biological and clinical practices for diagnostic and follow-up of ID patients.
Through study completion, an average of 10 years
Identification of a group of French patients with the same characteristics.
At inclusion
- +2 more other outcomes
Eligibility Criteria
All patients (adults and children) affected with an ID regardless of the severity of the disease, with a molecular characterization, with a signed informed consent for all subjects, followed in one partner's center.
You may qualify if:
- Patients (adults and children) affected with an ID regardless of the severity of the disease
- A confirmed diagnosis of ID (based on molecular diagnosis)
- A signed informed consent for adults or signed informed consent of parents/guardians of minors/ protected adult.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (20)
CHU d'Angers
Angers, France
Hôpital Jean Minjoz
Besançon, France
Hôpital Gabriel Montpied
Clermont-Ferrand, France
Hôpital Bicêtre
Le Kremlin-Bicêtre, France
Hôpital Jeanne de Flandre
Lille, France
Hôpital de la mère et de l'enfant
Limoges, France
Hôpital Femme Mère Enfant
Lyon, France
Hôpital de la Timone
Marseille, France
Hôpital Brabois
Nancy, France
Hôpital enfant-adolescent
Nantes, France
Hôpital Armand-Trousseau
Paris, France
Hôpital de la Pitié-Salpêtrière
Paris, France
Hôpital de la Pitié-Salpêtrière
Paris, France
Hôpital Necker Enfants Malades
Paris, France
Hôpital Robert Debré
Paris, France
Hôpital Sud
Rennes, France
Hôpital Civil
Strasbourg, France
Hôpital des Enfants
Toulouse, France
Hôpital des Enfants
Toulouse, France
Hôpital Bretonneau
Tours, France
Biospecimen
Stool collection
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Agnès LINGLART
Inserm U1169
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 26, 2023
First Posted
July 14, 2023
Study Start
March 10, 2017
Primary Completion (Estimated)
March 1, 2028
Study Completion (Estimated)
March 1, 2028
Last Updated
February 12, 2026
Record last verified: 2026-02